Medication info
Egliptin XR Sustained Release Tablet 50/500 Milligrams

Egliptin XR Sustained Release Tablet 50/500 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
(Co., Ltd.) Bibocron Pharmaceutical
Appearance
Bright blue oval sustained-release film-coated tablet with convex sides
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202201936 · Approved 2022.05.11 · Insurance code 658204630

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg extended-release tablet or the 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start this medicine at a dose of two 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is coadministered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
(Co., Ltd.) Bibocron Pharmaceutical

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes

View approved original text

This medication is used to help patients with type 2 diabetes control their blood sugar levels. It works effectively when combined with dietary and exercise therapies, as sitagliptin and metformin act together to manage blood sugar levels. This contributes to stabilizing blood sugar levels and reducing the risk of complications. Patients can expect better blood sugar control through consistent use and lifestyle improvements. This medication is indicated for the treatment of type 2 diabetes.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg extended-release tablet or the 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start this medicine at a dose of two 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is coadministered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains both sitagliptin and metformin and is used in the treatment of diabetes. Firstly, serious allergic reactions may occur during the use of this medication, so if any symptoms such as hives, rash, difficulty breathing, or swelling of the face or neck occur, it is important to stop taking the medication immediately and consult a doctor. Additionally, there is a risk of acute pancreatitis, which is inflammation of the pancreas, so if symptoms such as abdominal pain, vomiting, or nausea occur, one must go to the hospital immediately. Patients with significantly reduced kidney function or specific health conditions such as severe infections, heart failure, or acute myocardial infarction should not use this medication. This medication should be temporarily suspended before examinations using iodine contrast agents, and resumed only after confirming that kidney function is normal following examination. This medication should not be used by women who are pregnant, may become pregnant, or are breastfeeding. This medication can cause serious side effects such as hypoglycemia and lactic acidosis, so caution is needed if meals are skipped or there are irregular eating habits or vigorous exercise. In particular, elderly patients or those with weak kidney function need to undergo regular kidney function tests, and if kidney function deteriorates, the use of this medication should be stopped. During use, vitamin B12 levels may decrease, so it is advisable to confirm this through regular blood tests. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. If undergoing surgery, this medication should be stopped 48 hours before the operation and resumed only after normal oral intake and recovery of kidney function post-surgery. When used in conjunction with other diabetes medications or insulin, the risk of hypoglycemia may increase, so dose adjustments may be necessary as instructed by a doctor. During use, symptoms such as persistent diarrhea, vomiting, abdominal pain, headache, or upper respiratory infections may appear, so if these symptoms are severe, consult a doctor. Finally, this medication may not be fully absorbed and may be excreted in stool, so if the medication is found in stool, medical personnel should be informed.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infections
  • headache
Show 20 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • arthralgia with severity and disability
  • pemphigus-like blistering
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • hypoglycemic episodes
  • rash
  • urticaria
  • skin vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from exposure to air or moisture, and it is safe to store it at room temperature between 1 degree and 30 degrees Celsius. Maintaining appropriate temperature and container conditions will help preserve the effectiveness of the medication for a long time.

Appearance and packaging

Appearance

Bright blue oval sustained-release film-coated tablet with convex sides

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.